Moneycontrol
HomeNewsTrendsHow this fintech startup providing education loans navigated COVID-19 crisis
Trending Topics

How this fintech startup providing education loans navigated COVID-19 crisis

Coronavirus: When banks were worried about defaults after RBI announced a moratorium on loan repayments in 2020, Propelld saw an opportunity for growth by continuing lending.

February 19, 2022 / 11:29 IST
Story continues below Advertisement

The founders of education-focused fintech startup Propelld saw an opportunity for growth amid the coronavirus crisis. (Images: Propelld website and LinkedIn)

Millions of Indians were hit hard by the coronavirus lockdown in 2020. Jobs were lost as businesses shut down over fears of the fast-spreading disease, and people struggled to pay their debts.

To provide relief to borrowers, the Reserve Bank of India (RBI) announced a moratorium on repayments of loans from April to June. For lenders who would have to deal with defaults, the situation was precarious.

Story continues below Advertisement

Small lenders would be impacted even more deeply. Among them was Propelld, a fintech startup focusing on education. It was founded by three friends from IIT Madras with the objective of profitably funding the education of those who could not afford it.

A Twitter thread from a Ritesh Banglani, who was a member of the board of Propelld, detailed how the enterprise navigated the situation.

“The company had exposure to some of the most vulnerable borrowers during the pandemic --- children of shopkeepers, auto drivers and schoolteachers,” he said. “There's no way they would be able to continue servicing their education loans.”

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show